Open AccessPublished:March 28, 2019DOI:https://doi.org/10.1016/S1473-3099(18)30730-8
The Lancet Infectious Diseases
Cerebrum. 2016 Jul-Aug; 2016: cer-10-16.
Published online 2016 Jul 1.
https://www.researchgate.net/publication/47460246_Mental_illness-stigma_and_discrimination_in_Zambia
BMC Family Practice (2017) 18:56 DOI 10.1186/s12875-017-0628
BJPSYCH INTERNATIONALVOLUME 12NUMBER 4NOVEMBER 2015
Les programmes de planification familiale sont une solution gagnant-gagnant ; le bien-être de chaque femme et des enfants est amélioré, et l'économie nationale et l'environnement en tirentles bénéfices
BMJ Global Health2019;4:e001504. doi:10.1136/bmjgh-2019-00150
Bull World Health Organ 2016;94:554–556 | doi: http://dx.doi.org/10.2471/BLT.15.162610
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...s of the clinical trials of fexinidazole. The screening of the Drugs for Neglected Diseases initiative (DNDi) HAT-library by the Swiss TPH had singled out fexinidazole, originally developed by Hoechst (now Sanofi), as the most promising of a series of over 800 nitroimidazoles and related molecules. In cell culture, fexinidazole has an IC50 of around 1 µM against Trypanosoma brucei and is more than 100-fold less toxic to mammalian cells. In the mouse model, fexinidazole cures both the first, haemolymphatic, and the second, meningoencephalitic stage of the infection, the latter at 100 mg/kg twice daily for 5 days. In patients, the clinical trials managed by DNDi and supported by Swiss TPH mainly conducted in the Democratic Republic of the Congo demonstrated that oral fexinidazole is safe and effective for use against first- and early second-stage sleeping sickness. Based on the positive opinion issued by the European Medicines Agency in 2018, the WHO has released new interim guidelines for the treatment of HAT including fexinidazole as the new therapy for first-stage and non-severe second-stage sleeping sickness caused by Trypanosoma brucei gambiense (gHAT). This greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
more
Lancet 2013; 381: 1405–16
Series: Childhood Pneumonia and Diarrhoea no.1
Public health Panoram, Vol.2 Issue 1 March 2016
BMC Public Health (2018) 18:668 https://doi.org/10.1186/s12889-018-5594-3
Lancet. 2018 Dec 19. pii: S0140-6736(18)31647-7. doi: 10.1016/S0140-6736(18)31647-7. [Epub ahead of print]
Rund drei Viertel der in Deutschland lebenden Flüchtlinge aus Syrien, dem Irak und Afghanistan sind nach Gewalterlebnissen traumatisiert.
DOI http://dx.doi.org/ 10.1055/s-0030-1256439 Online-Publikation: 10. 5. 2011 Pneumologie 2011; 65: 359–378
Accessed January 22, 2019.
This updated version include important research that has added to our knowledge about effective treatments for
child and adolescent depression. Its goal is to help parents and families make informed decisions about getting the best care for a child with depression. For ...easy use, it is presented in Frequently Asked Questions (FAQ) format.
more
El objetivo fue determinar cuáles son las percepciones de distintos actores del sistema de salud
colombiano sobre los problemas del sistema que están detrás de la crisis. Se realizó un estudio
cualitativo a partir de entrevistas semiestructuradas y en profundidad con cuarenta agentes del
sect...or salud, en Bogotá, Cali, Ibagué, Espinal y Calima-Darién. Los resultados mostraron que la
corrupción, el incumplimiento de normas y los conflictos entre los intereses de diversos actores
del sistema debilitan la legitimidad de este último, atomizan la cooperación y cohesión de los
actores y fortalecen el interés particular.
more
Gurejeet al. BMC Health Services Research (2015) 15:242
DOI 10.1186/s12913-015-0911-3